To our knowledge, this is the first report of a patient with non‐small cell lung cancer harboring
an HLA‐DRB1‐MET gene fusion demonstrating a clinical response to multiple MET …

Background: Public health measures have imposed drastic reductions in cancer screening
programs at the beginning of the COVID-19 pandemic, with an unknown impact on the …

Background Fluoropyrimidines are used in chemotherapy combinations for multiple cancers.
Deficient dihydropyrimidine dehydrogenase activity can lead to severe life‐threatening …

Background Management of Non-Small Cell Lung Cancer (NSCLC) patients with
oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic …

… infusional 5-FU 1000 mg/m 2 on days 1–4 and 29–32 plus MMC 10 mg/m 2 on day 1 and 29
… Acceptable dosing of MMC may be either 10 mg/m 2 on day 1 and 29 or 12 mg/m 2 on day …

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in
Halifax, Nova Scotia, 20–22 September 2018. Experts in radiation oncology, medical …

METHODS This was a retrospective analysis approved by the research ethics board of the
Centre hospitalier de l’Université de Montréal. All patients with abdominal neoplasms with …

… Mustapha Tehfé Mustapha Tehfé … Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W,
et al. Coagulopathy and antiphospholipid antibodies in patients with covid-19. 2020:e38. …

Methods We retrospectively reviewed the Université de Montréal Health Center’s (CHUM)
oncology database for patients with NSCLC who undergone NGS analysis from July 2014 to …

Lung cancer is the most commonly diagnosed cancer in Canada and remains associated
with high mortality. Nevertheless, advances over the last decade in the fields of immuno-…